The FDA unveiled a pilot program designed to expedite Phase I trial initiation by pairing sponsors with prequalified research institutions. Under the model, the agency will select eight to ten projects, then allow rolling pre-IND and individualized component reviews during the pre-IND phase rather than waiting for all elements to be complete. The program is intended to reduce lag between IND preparation and first-in-human start dates, and it also targets parallel work streams such as Institutional Review Board assessments and site activation. The FDA framed the QRIs as bringing specialized scientific expertise into IND application preparation. For biotech teams, the update matters because early-phase timelines can determine investor confidence and downstream patient enrollment readiness. The pilot also signals the FDA’s willingness to adapt IND mechanics to reduce administrative bottlenecks.